Paydirt
GC
Insider

GC Corp.

10% owner

GC Corp. (10% owner) filed 1 Form 4 report as a reporting entity in the trailing twelve months (1 purchase, 0 sales, 1 filed past the two-business-day deadline), most often in Artiva Biotherapeutics, Inc. (ARTV). Across 1 priced purchase filing, the average 21-session return was -37.8% from execution and +26.2% from disclosure (delay-adjusted; derived). The largest single filing was $16.5M of ARTV (1,432,291 sh across 2 lots, as filed), executed May 11.

Add to watchlist
Return, ttmiAverage return per filing, trailing twelve months
-37.8%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+26.2%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells · 1 late
Median delay
17d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$16.5M
shares × price, as filed
Last traded
May 11
Filed May 28

Median ADV $6.3M across their filed names

Open performance
Volume by month
$16.5M$8.2M$0Oct 2024Apr 2025Oct 2025Apr 2026May 2026 · buys $16.5M
Buys $16.5M Sells $0

Shares × price, as filed · by filing month · past 24 months

Sectors filed on
Healthcare 1 filing

Sector per market data · by filing · past 12 months

Most traded names
ARTV Artiva Biotherapeutics, Inc. ARTV · 1 buy · 0 sells 1 filing
Recent filings
ARTVPURCHASE Artiva Biotherapeutics, Inc. View filing → $16.5M
1,432,291 sh across 2 lots
Exec May 11
Filed May 28 · 4:34 PM ET †